Sleep device maker ResMed ramps up doctor outreach to tap Ozempic surge

Sleep-breathing device maker ResMed plans to take global a doctor education program aimed at promoting the screening of patients seeking Ozempic-style weight loss drugs for apnea, calling the GLP‑1 boom a lift, not a threat, to sales.

Reuters • 7 hours ago

Novo Nordisk says CagriSema outperforms semaglutide in late-stage trial of type-2 diabetes patients

Novo Nordisk said on Monday its experimental next-generation weight-loss drug CagriSema reduced blood sugar levels and body weight more than semaglutide alone in a late-stage trial of patients with type 2 diabetes.

Reuters • 20 hours ago

Is Novo Nordisk Stock a Bargain Right Now?

Novo Nordisk was a leader in GLP-1 weight loss but was displaced by Eli Lilly. Investors have punished Novo Nordisk's stock, with the shares having lost more than half their value since mid-2024.

The Motley Fool • 17 hours ago

Obesity market sales potential tightens as Novo and Lilly enter new era

The long-held Wall Street expectation that the global market for obesity drugs would reach $150 billion in the next decade is looking a lot less certain with U.S. prices falling for GLP-1 treatments from Novo Nordisk and Eli Lilly and competition heating up in the cash-pay consumer market.

Reuters • Feb 2, 2026

Novo Nordisk A/S: CagriSema demonstrated superior HbA1c reduction of 1.91%-points and weight loss of 14.2% in adults with type 2 diabetes in the REIMAGINE 2 trial

CagriSema achieved superior weight loss of up to 14.2%, where up to 43% of the people achieved ≥15% weight loss and up to 24% achieved ≥20% weight loss1. CagriSema achieved superior HbA1c reduction of up to 1.91%-points1 from a mean HbA1c baseline of 8.2%.

GlobeNewsWire • 20 hours ago

What's in Store for These 5 Pharma Bigwigs This Earnings Season?

As earnings season accelerates, pharma heavyweights LLY, MRK, NVO, BMY and PFE prepare to reveal their Q4 results amid a strong sector start.

Zacks Investment Research • 20 hours ago

Should You Buy Novo Nordisk Stock on Oral Wegovy's Strong Launch?

In December, it earned approval for the oral version of its famous medicine. Novo Nordisk's newest product launch is proving very popular.

The Motley Fool • Jan 31, 2026

Novo's Wegovy pill tracks over 26,000 prescriptions

Novo Nordisk's Wegovy pill hits over 26,000 U.S. prescriptions in the second full week after its launch, IQVIA data shared by an analyst on Friday showed.

Reuters • Jan 30, 2026

Novo Nordisk's China President Zhou to step down in March

Danish pharmaceutical company Novo Nordisk said on Friday that Senior Vice President and head of its business in China Christine Zhou will leave the company at the end of March.

Reuters • Jan 30, 2026

New play in Denmark charts Novo Nordisk's weight loss boom

A play examining the meteoric rise of Danish weight-loss drug giant Novo Nordisk will premiere on Saturday at a theatre outside Copenhagen.

Reuters • Jan 30, 2026